Statistical analysis
REGRESSION, DISEASE CHARACTERISTIC
Baseline demographic and disease characteristics were described with summary descriptive statistics. Kaplan–Meier analyses were used to estimate the probability of golimumab persistence over time by study, indication, and line of therapy. Group differences in these analyses were evaluated by the log-rank test. Golimumab persistence rates were determined at baseline (Week 0), Year 1 (Week 52), Year 2 (Week 104), Year 3 (Week 156), Year 4 (Week 208), and Year 5 (Week 252) for all studies. A multivariate Cox regression model was used to analyze predictive factors related to overall golimumab persistence, which was built using the purposeful selection process and stepwise selection method. All analyses were performed using SAS version 9.4. No adjustments for multiplicity were made.